グルカゴン様ペプチド2受容体治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0420
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Glucagon Like Peptide 2 Receptor – Pipeline Review, H2 2019
Summary

Glucagon Like Peptide 2 Receptor (GLP2R) – Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 5, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Toxicology, Immunology, Musculoskeletal Disorders and Other Diseases which include indications Short Bowel Syndrome, Chemotherapy Effects, Chemotherapy-Induced Diarrhea (CID), Crohn’s Disease (Regional Enteritis), Gastrointestinal Mucositis, Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) and Osteoporosis.

The latest report Glucagon Like Peptide 2 Receptor – Pipeline Review, H2 2019, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) – Overview
Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) – Companies Involved in Therapeutics Development
Adocia SAS
Bainan Biotech ApS
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
Naia Rare Diseases Inc
OPKO Health Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Sosei Heptares
Takeda Pharmaceutical Co Ltd
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) – Drug Profiles
apraglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elsiglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GLP2R for Intestinal Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-681 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-7570 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucagon Like Peptide 2 Receptor (GLP2R) – Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) – Product Development Milestones
Featured News & Press Releases
Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
May 03, 2019: Hanmi’s short bowel syndrome treatment becomes orphan drug in US
Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome
Nov 13, 2018: U.S. FDA accepts for filing Shire’s supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome
Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland
Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adocia SAS, H2 2019
Pipeline by Bainan Biotech ApS, H2 2019
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Pipeline by Huons Global Co Ltd, H2 2019
Pipeline by Naia Rare Diseases Inc, H2 2019
Pipeline by OPKO Health Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Pipeline by Sosei Heptares, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Zealand Pharma AS, H2 2019
Dormant Projects, H2 2019

【掲載企業】

Adocia SAS
Bainan Biotech ApS
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
Naia Rare Diseases Inc
OPKO Health Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Sosei Heptares
Takeda Pharmaceutical Co Ltd
Zealand Pharma AS

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[グルカゴン様ペプチド2受容体治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆